pegademase-bovine

Trade name: Adagen

Animal productapprovedOrphan Drug FDA

Approved

Mar 21, 1990

Clinical trial activity

2 trials · 4 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Nov 1, 2008 (NCT00794508)

Timeline

1980s

  1. May 29, 1984

    Orphan Drug Designation

1990s

  1. Mar 21, 1990

    Leadiant Biosciences, Inc. — Earliest FDA Approval

  2. Mar 21, 1990

    Leadiant Biosciences, Inc. — NDA Secondary Org

  3. Mar 21, 1990

    Leadiant Biosciences, Inc. — NDA Organization

2000s

  1. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Leadiant Biosciences, Inc. — Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedMar 21, 1990

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • adagen
  • adagen
  • adagen
  • adenosine aminohydrolase
  • adenosine deaminase
  • pegada
  • peg-ada
  • pegademase
  • pegademase bovine
  • pegademase bovine
  • pegademase bovine
  • pegademase bovine
  • pegademase-bovine
  • polyethylene glycol-modified adenosine deaminase

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01420627Phase 3Dec 1, 2013Leadiant Biosciences, Inc.
NCT00794508Phase 2Nov 1, 2008Food and Drug Administration, National Institutes of Health (NIH), University of California, Los Angeles
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Food and Drug AdministrationGovernment1012008
Leadiant Biosciences, Inc.For profit1112013
National Institutes of Health (NIH)Government1012008
University of California, Los AngelesAcademic/Hospital1112008
4 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
Leadiant Biosciences, Inc.For profitNDA2Mar 21, 1990
Leadiant Biosciences, Inc.For profitNDAMar 21, 1990